Show simple item record

dc.contributor.authorHOLLYWOOD, DONAL
dc.contributor.authorFOLEY, RUTH
dc.date.accessioned2011-09-01T13:44:02Z
dc.date.available2011-09-01T13:44:02Z
dc.date.issued2011
dc.date.submitted2011en
dc.identifier.citationFoley R, Keane J, O Mathuna DP, Hollywood D., Endothelin inhibitors for advanced prostate cancer, Cochrane Database of Systematic Reviews, 8, CD009193, 2011en
dc.identifier.otherY
dc.descriptionPUBLISHEDen
dc.description.abstractThis is the protocol for a review and there is no abstract. The objectives are as follows: Our review aims to determine the effectiveness and adverse effects of endothelin inhibitors for advanced prostate cancer. The primary objectives are to assess the effect of endothelin inhibitors on overall survival, prostate cancer-speci?c survival, and progression-free survival. The secondary objectives are to determine: 1. the frequency of adverse events; 2. the effect of treatment on target lesions identi?ed by radiological imaging; 3. the effect of treatment on molecular biomarkers, including PSA and bone alkaline phosphatase; 4. the impact on quality of life.en
dc.language.isoenen
dc.publisherJohn Wileyen
dc.relation.ispartofseriesCochrane Database of Systematic Reviews;
dc.relation.ispartofseries8;
dc.relation.ispartofseriesCD009193;
dc.rightsYen
dc.subjectOncologyen
dc.subjectProstate canceren
dc.titleEndothelin inhibitors for advanced prostate canceren
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/edgarr
dc.identifier.peoplefinderurlhttp://people.tcd.ie/dhlywood
dc.identifier.rssinternalid74789
dc.identifier.rssurihttp://dx.doi.org/10.1002/14651858.CD009193en
dc.contributor.sponsorHealth Research Boarden
dc.identifier.urihttp://hdl.handle.net/2262/59207


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record